

COSMO PHARMACEUTICALS NV

ISIN: NL0011832936 WKN: 32590356 Asset Class: **Stock**

Company

2024/07/09 10:34:41



Price

71.60 CHF

Difference ▲ 0.56%(0.40)



Contact Details

COSMO PHARMACEUTICALS NV

Tel: +353-1-8170370

--

Fax: +353-1-8230718

Riverside II, Sir John

Web:

Rogerson's Quay

<http://www.cosmopharma.com>

2 Dublin

E-mail: -

Company Profile

Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	302,246,000		285,823,000		273,491,000	
Common stock capital		4,504,000		4,726,000		4,228,000
Fixed assets	447,789,000		548,867,000		371,290,000	
Equity capital of a company		451,030,000		523,951,000		425,175,000
Cash and cash equivalents	183,487,000		205,739,000		201,101,000	
Accrued liabilities		400,000		496,000		406,000
Other assets	-		-		-	
Current liabilities		192,493,000		22,003,000		23,570,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		106,511,000		288,735,000		196,036,000
Different income		-		-		-
Other liabilities		1,564,000		2,478,000		2,587,000
Total assets	750,036,000	750,036,000	834,690,000	834,690,000	644,782,000	644,782,000

Balance notes

	2022	2021	2020
Accounting standard	IFRS	IFRS	IFRS
Employees	295	290	265
Equity ratio	61.04%	63.69%	65.94%
Debt-equity ratio	63.83%	57.01%	51.65%

Others

	2022	2021	2020
Tax Expense Rate	28.47%	34.22%	-48.74%

COSMO PHARMACEUTICALS NV

ISIN: NL0011832936 WKN: 32590356 Asset Class: Stock

Income statement

	2022	2021	2020
Turnover	102,471,000	70,321,000	65,215,000
Net income	17,289,000	23,419,000	-8,454,000
EBIT	31,772,859	14,862,548	5,680,160
Operating income before taxes	24,564,000	7,358,000	-2,129,000
Cash Flow	31,100,000	12,209,000	10,084,000
Net interest income	-6,354,000	-7,105,000	-7,656,000
Research and development expenses	11,589,000	8,208,000	14,548,000
Income taxes	6,994,000	2,517,000	1,037,000
Result from investments in subsidiaries, associates and other	0	18,580,000	-5,286,000
Revenues per employee	356,949	249,182	252,887

Board of Directors

Alessandro Chà	Chairman of Supervisory Board
John O'SDea	Member of Supervisory Board
Maria Grazia Roncarolo	Member of Supervisory Board
Mauro Ajani	Member of Supervisory Board
Niall Donnelly	Member of Supervisory Board
Silvana Perretta	Member of Supervisory Board

Members of Management Board

Alessandro Della Cha	Chairman of Managing Board
Biagio Viganò	Member of Executive Committee
Luigi Longo	Member of Executive Committee
Marco Lecchi	Member of Executive Committee
Niall Donnelly	Member of Executive Committee
Roberto Villa	Member of Executive Committee